Published

Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Frontiers in psychiatry
Date: 2022-01-01
Source: PubMed
DOI: 10.3389/fpsyt.2022.831092
PubMed: 35370864

Authors

Raison CL Jain R Penn AD Cole SP Jain S

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Wellbeing Emotional Processing Mystical Experience Clinical Trial Observational Study Safety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 3 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services2026-08-19 Psilocybin-assisted psychotherapy for substance use disorders as a complex intervention: A systematic review of efficacy, mechanisms and psychotherapeutic frameworks2026-08-17 Psilocin alleviates acute itch in mice: possible involvement of 5-HT2A receptors and kynurenine pathway2025-10-01

Related papers

Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-ControlClinicalTrials.gov · 2026-05-04 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderClinicalTrials.gov · 2025-08-19 Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-07-23